Article 30 Referral in EU Medicines Regulation

Overall structure

This article is organised around the actual regulatory lifecycle of an Article 30 referral rather than a collection of isolated procedural definitions.

1. What an Article 30 referral is and why it exists
2. The legal trigger: divergent national decisions concerning the same medicinal product
3. Distinguishing Article 30 from Articles 29(4), 31 and other referral mechanisms
4. Who can initiate the referral and how the formal notification works
5. Determining the products, applications and national decisions within scope
6. CHMP organisation, rapporteurs, questions and scientific assessment
7. Harmonisation of indications, posology, contraindications, warnings and other product information
8. Quality, efficacy and safety evidence underlying the divergence
9. MAH/applicant responses, re-examination and procedural rights
10. CHMP opinion, European Commission decision and national implementation
11. Practical implementation across nationally authorised products
12. Product-information and regulatory-document updates
13. CMDh and Member State roles after the Union decision
14. Audit trail, governance and inspection readiness
15. Common regulatory misreadings
16. Reading primary EMA and EU documents correctly
17. Relationship with lifecycle variations and other procedures
18. Practical checklist for regulatory professionals
19. References and primary-document hierarchy
20. Regulatory note

1. What Is an Article 30 Referral?

Article 30 of Directive 2001/83/EC provides a Union-level mechanism for addressing certain divergent national decisions concerning a particular medicinal product.

The statutory situation arises where two or more applications for marketing authorisation for the same medicinal product have resulted in divergent decisions by Member States concerning matters such as authorisation, suspension or revocation.

In those circumstances, the matter can be referred to the Committee for Medicinal Products for Human Use (CHMP) for assessment under the Union referral procedure.

The defining feature is therefore not simply that Member States have different wording in their licences. It is that the divergence falls within the statutory conditions of Article 30.

A simplified lifecycle is:

Divergent national regulatory decisions
                ↓
        Article 30 referral
                ↓
              CHMP
                ↓
       Scientific assessment
                ↓
          CHMP opinion
                ↓
 European Commission decision, where applicable
                ↓
      National implementation

Article 30 is consequently best understood as a harmonisation mechanism for qualifying national regulatory divergences.

2. Why Does Article 30 Exist?

The EU medicines framework allows medicinal products to be authorised nationally in several Member States. Over time, the regulatory histories of those authorisations can diverge.

Differences can arise because:

• applications were assessed separately;
• regulatory decisions were taken at different times;
• scientific evidence evolved after individual national decisions;
• Member States interpreted evidence differently;
• product information was amended differently during the product lifecycle;
• national regulatory histories developed independently.

Without a Union-level mechanism, materially different regulatory positions could persist for the same medicinal product.

Article 30 provides a route for bringing the qualifying divergence before CHMP so that the underlying scientific and regulatory question can be assessed at Union level.

The objective is therefore harmonisation based on a common scientific assessment, not simply administrative standardisation.

3. The Legal Basis

The primary legal basis is Article 30 of Directive 2001/83/EC, read together with the subsequent referral provisions governing the Union assessment and decision-making process.

Article 30 identifies the circumstances in which a divergent national regulatory position can be referred to CHMP. The subsequent provisions govern the conduct of the referral, the committee opinion and the decision-making stage.

This distinction is useful because Article 30 itself describes the trigger, while the later articles describe much of the procedure that follows.

For a live procedure, the current consolidated text of Directive 2001/83/EC should always be consulted rather than relying on a secondary description of the legislation.

4. What Is a Divergent National Decision?

A qualifying divergence exists when Member States have adopted different regulatory decisions concerning the same medicinal product in circumstances falling within Article 30.

Examples can include differences concerning:

• whether a marketing authorisation should be granted;
• whether an authorisation should be suspended;
• whether an authorisation should be revoked;
• particular elements of the authorised conditions of use where those differences reflect divergent regulatory decisions.

Not every textual difference between national product information necessarily establishes an Article 30 referral situation.

The relevant question is whether the underlying national regulatory positions fall within the statutory scope of Article 30.

This is why the regulatory history and the decisions themselves should be examined rather than identifying a referral solely from differences in wording.

5. Article 30 and Product Information

Product information is a frequent practical focus of Article 30 procedures because different national regulatory decisions can result in materially different authorised information.

Potential areas of divergence include:

• therapeutic indication;
• target population;
• posology;
• contraindications;
• warnings and precautions;
• special-population information;
• adverse-reaction information;
• labelling;
• package leaflet.

Where the divergence falls within Article 30, CHMP can assess the evidence underlying the different national positions and establish a harmonised regulatory position.

The important point is that product-information harmonisation is an outcome of the scientific and regulatory assessment, not an independent formatting exercise.

6. Article 30 Is Not the Same as Article 29(4)

Article 30 and Article 29(4) can both involve nationally authorised medicines and CHMP, but their legal triggers are different.

Article 29(4) is therefore an escalation from an unresolved MRP/DCP disagreement.

Article 30 addresses a different situation: qualifying divergence between national regulatory decisions that already exist.

7. Article 30 and Article 31

Article 31 is a broader Union referral mechanism with its own statutory triggers, including the specific pharmacovigilance pathway.

Article 30 is narrower in its defining characteristic because it starts from divergent national decisions concerning the same medicinal product.

The distinction can be summarised as:

Article 30
Divergent national regulatory decisions
                ↓
              CHMP

Article 31 PV
Pharmacovigilance data / safety concern
                ↓
              PRAC
                ↓
        subsequent regulatory pathway

A safety issue can be present in an Article 30 procedure, but Article 30 is not itself a pharmacovigilance referral mechanism.

The correct legal classification should therefore be based on the formal referral and its statutory basis.

8. Who Can Initiate an Article 30 Referral?

Article 30 provides several possible routes into the referral procedure. Depending on the statutory conditions, a matter can be referred by:

• a Member State;
• the European Commission;
• the applicant; or
• the marketing authorisation holder.

This is materially different from a procedure that can arise only through a specific national regulatory escalation mechanism.

For an MAH or applicant, the practical significance is that the Union framework provides a route for resolving qualifying national divergences rather than requiring the company to manage permanently different regulatory positions independently in each Member State.

The formal referral notification remains the procedural anchor regardless of who initiates it.

9. When Can the Marketing Authorisation Holder Initiate?

Where the statutory conditions are satisfied, the MAH can refer a qualifying divergence to CHMP.

This can be particularly relevant when the same medicinal product has developed materially different national regulatory positions during its lifecycle.

The MAH should document:

• the national authorisations concerned;
• the decisions that diverge;
• the regulatory subject of the divergence;
• the scientific basis for seeking Union assessment;
• the proposed harmonised position where appropriate.

The existence of a divergence should be demonstrated from the underlying national regulatory record rather than inferred merely from different versions of product information.

10. The Formal Referral Notification

Once the Article 30 procedure is formally initiated, the referral notification defines the issue that CHMP is being asked to examine.

For regulatory control purposes, the referral record should capture:

• legal basis;
• date of referral;
• initiating party;
• medicinal product and active substance;
• affected marketing authorisations;
• Member States concerned;
• nature of the divergence;
• formal questions or scope;
• relevant supporting evidence.

The notification should be treated as the procedural starting point when reconstructing the referral timeline.

The date on which the underlying divergence first arose may be much earlier than the formal referral date. Those dates should not be conflated.

11. The MAH Contact Point and Procedural Communications

The marketing authorisation holder (MAH) or applicant should establish a clear contact point for communication with the Agency before the Article 30 referral begins.

Current EMA guidance states that the designated contact person should be registered in the IRIS platform before the start of the procedure. The contact person receives the procedural correspondence and can be changed during the procedure by updating the submission contact in IRIS and informing the relevant EMA procedure contacts.

This is not merely an administrative convenience. EMA documentation made available through IRIS can constitute effective receipt for procedural purposes, including the calculation of applicable timelines.

For regulatory governance, the company should therefore ensure that:

• the correct MAH or applicant contact is registered;
• the contact has access to IRIS;
• responsibility for monitoring procedural correspondence is explicit;
• backup arrangements exist within the regulatory organisation;
• procedural deadlines are captured in the company's tracking system.

A referral should never depend on an individual person's informal monitoring of email or meeting publications.

12. Announcement of the Start of the Referral

Following receipt of the notification initiating an Article 30 referral, the divergence is considered at the upcoming CHMP plenary meeting.

The start of the procedure is announced through EMA's established publication channels. The announcement identifies the concerns under consideration and is associated with a procedure-specific page.

The public announcement is important for regulatory surveillance because it establishes the externally visible start of the Union procedure. It should nevertheless be distinguished from the earlier national regulatory decisions that created the divergence.

A regulatory timeline should therefore record at least three different dates where applicable:

1. the date of the underlying national decision or decisions;
2. the date on which the referral notification was submitted;
3. the formal start of the Article 30 procedure.

These dates can have different legal and operational significance.

13. Identifying the Products Within Scope

For an Article 30 referral, the scope is centred on the medicinal product for which divergent national decisions have been adopted concerning its authorisation, suspension or revocation.

EMA requests the MAH to provide information identifying the affected presentations and national authorisations. This can include:

• invented name;
• company name in each Member State;
• strength;
• pharmaceutical form;
• route of administration;
• relevant content or presentation information;
• Member States in which the product is authorised.

The information is checked with the relevant national competent authorities.

The practical principle is straightforward: scope is established from the regulatory record, not from the MAH's commercial product list alone.

Parallel Article 30 referrals may also be considered in certain circumstances involving different salt forms, pharmaceutical alternatives, single active substances and fixed combinations where the regulatory or scientific relationship between the products justifies a coordinated assessment.

14. Pending Variations and Other Regulatory Procedures

An Article 30 referral does not exist in isolation from the product's wider regulatory lifecycle.

Pending variations should be identified at the pre-referral stage and in the referral submission. According to current EMA guidance, a submitted variation is taken into account during the referral only where it has been approved in at least one Member State, including Iceland and Norway where applicable.

Other ongoing regulatory activities should also be made visible to the Agency and the rapporteurs. These can include:

• paediatric submissions;
• paediatric work-sharing activities;
• PSUR submissions;
• annual reassessments;
• other relevant lifecycle procedures.

The purpose is to prevent parallel regulatory activity from being interpreted without knowledge of the latest authorised position.

For an MAH, the practical requirement is therefore to create a single regulatory inventory of all live procedures affecting the product before the referral begins.

15. The MAH Submission to the Referral

The MAH or applicant is expected to provide the evidence relevant to the assessment.

Where the referral is triggered by a Member State or the European Commission, CHMP normally identifies the information required through a List of Questions (LoQ). The MAH then prepares responses within the timetable established for the procedure.

Where the MAH or applicant itself initiates the referral, the initial submission is particularly important because the company is expected to provide the documentation necessary to explain the divergences and justify the proposed harmonisation.

In a referral concerning divergent product information, the submission should address the national differences explicitly rather than presenting only the company's preferred wording.

A useful submission architecture is:

Referral question
       ↓
Current national positions
       ↓
Nature of divergence
       ↓
Scientific evidence
       ↓
Regulatory analysis
       ↓
Proposed harmonised position
       ↓
Justification for each material wording change

This structure makes it possible for the rapporteurs to trace the proposed harmonisation back to the underlying evidence.

16. Harmonised Product Information Proposal

Where the referral concerns divergent product information, the MAH should provide a proposed harmonised Summary of Product Characteristics (SmPC), labelling and package leaflet, as applicable.

The submission should also describe the divergence across Member States for the relevant SmPC sections and provide the scientific rationale for the proposed harmonised wording.

This is particularly important where the company proposes to remove wording that currently exists in one or more Member States.

The justification should explain:

• what the existing wording is;
• where it is authorised;
• why the wording differs between Member States;
• what evidence supports the proposed harmonised wording;
• why wording currently present in a Member State should or should not be retained.

Product-information harmonisation is therefore an evidence-based regulatory exercise, not simply an editorial comparison of national texts.

17. How CHMP Gathers the Evidence

At the beginning of the procedure, CHMP identifies the information needed for the assessment and, where applicable, adopts a List of Questions.

The questions define the principal information requests to the MAH or applicant and establish the response timetable.

CHMP can subsequently request further information through a List of Outstanding Issues or additional questions. An oral explanation may also be used where the applicable procedure provides for it.

The assessment can therefore develop iteratively:

Initial referral
      ↓
Initial evidence
      ↓
CHMP List of Questions
      ↓
MAH responses
      ↓
Rapporteur assessment
      ↓
Outstanding issues, if required
      ↓
Additional responses / oral explanation
      ↓
CHMP opinion

The existence of additional questions should not automatically be interpreted as a negative regulatory signal. It means that the committee considers further clarification necessary before it can reach its conclusion.

18. CHMP Rapporteurs and Scientific Assessment

CHMP appoints a rapporteur and co-rapporteurs for the Article 30 procedure. Current EMA guidance states that these appointments are made by the CHMP Chairperson from among CHMP members or alternates, with the aim of applying the best available expertise to the individual procedure.

The rapporteurs lead the detailed scientific assessment of the evidence submitted during the procedure.

Depending on the nature of the divergence, the assessment can involve:

• clinical evidence;
• non-clinical evidence;
• quality data;
• pharmacological evidence;
• regulatory history;
• national assessment conclusions;
• published literature;
• post-authorisation evidence;
• proposed product-information wording.

The rapporteur assessment is prepared for consideration by the full committee. It is not itself the final CHMP opinion.

This distinction is important when reading procedure documents: an assessment report represents the scientific evaluation undertaken by the rapporteurs, whereas the adopted CHMP opinion represents the committee's formal conclusion.

19. The List of Questions and List of Outstanding Issues

The List of Questions (LoQ) is a central procedural document.

It identifies the matters for which CHMP requires information or clarification from the MAH or applicant. The response should follow the numbering of the questions so that each regulatory issue can be traced through the assessment.

If material issues remain unresolved after the initial response, CHMP may adopt a List of Outstanding Issues (LoOI).

The distinction is operationally important:

A regulatory team should maintain an issue-by-issue tracker connecting each question to the evidence supplied, the company's position, the rapporteur assessment and the eventual resolution.

This provides an auditable chain from regulatory question to regulatory conclusion.

20. Format and Quality of the MAH Response

Current EMA guidance expects referral submissions to be provided electronically in the applicable CTD/eCTD structure and accompanied by a signed cover letter and a written summary addressing each question.

The response should clearly identify the Article 30 procedure and the relevant question number. Supporting evidence should be placed within the appropriate CTD structure, with working documents provided where required to facilitate assessment.

For a product-information divergence, the submission should include, as applicable:

• the proposed harmonised SmPC;
• proposed harmonised labelling;
• proposed harmonised package leaflet;
• a description of national divergences;
• the scientific rationale for the proposed wording;
• supporting evidence.

All submitted evidence remains the responsibility of the MAH or applicant. The quality of the submission can materially affect the efficiency and clarity of the scientific assessment.

The response should therefore be internally controlled for:

• completeness;
• consistency between modules;
• consistency with the authorised regulatory history;
• traceability of claims to evidence;
• consistency between scientific conclusions and proposed product information;
• correct procedural references.

21. Submission Through EMA's Electronic Systems

Current EMA guidance states that referral responses should be submitted through the eSubmission Gateway or eSubmission Web Client using the applicable XML delivery files.

Successful electronic submission generates an acknowledgement of receipt. Where no acknowledgement is received, the submission should not simply be assumed to have been delivered successfully.

This creates a practical regulatory control point.

The MAH should retain evidence of:

• the submitted package;
• the submission date and time;
• the delivery mechanism;
• the acknowledgement of receipt;
• the final submitted version;
• any subsequent corrected submission.

Electronic submission records form part of the procedural audit trail and should be retained in accordance with the company's regulatory records-management requirements.

22. The Article 30 Assessment Timetable

For referrals initiated by a Member State or the European Commission, current EMA guidance describes a timetable in which notification is Day 0 and the first CHMP discussion occurs at Day 1.

At the first meeting, CHMP addresses the divergence, confirms or appoints the rapporteurs and adopts the List of Questions and timetable where applicable.

Following the MAH response and restart of the procedure, the rapporteur assessment reports are circulated. CHMP members then provide comments before the committee discusses whether to adopt an opinion or issue a List of Outstanding Issues.

For the standard timetable described by EMA, the principal milestones are approximately:

Day 0       Notification
Day 1       First CHMP discussion / LoQ / timetable
Clock stop  MAH prepares responses
Day 20      Rapporteur assessment reports
Day 25      CHMP comments
Day 30      CHMP discussion
            ↓
       Opinion, or LoOI
            ↓
Clock stop  Further responses if required
Day 60      CHMP opinion where LoOI procedure is used

These are guidance timelines rather than a substitute for the timetable of the individual procedure.

23. Article 30 Referrals Initiated by the MAH or Applicant

The timetable differs when the MAH or applicant initiates the Article 30 referral.

In this situation, the procedure starts with the Agency working with the MAH or applicant to ensure that the relevant documentation is available for CHMP assessment.

At the first CHMP meeting, provided that the documentation has been submitted in advance, the committee discusses the divergence, appoints or confirms the rapporteurs and adopts the timetable for assessment of the documentation already submitted.

The absence of an initial CHMP List of Questions in this pathway does not mean that the assessment is less rigorous. It reflects the fact that the initiating MAH or applicant has already submitted the material needed to explain the divergence and proposed harmonisation.

The exact dates should always be taken from the procedure-specific timetable.

24. Assessment Reports and Access by the MAH

The rapporteur assessment reports are important procedural documents because they show how the evidence has been evaluated before the matter is brought to the full committee.

Current EMA guidance states that the MAH or applicant receives the CHMP rapporteur assessment report(s) through the IRIS platform.

The company's regulatory response should therefore be capable of being updated rapidly when the assessment reveals a scientific interpretation that differs from the company's original position.

A useful internal process is:

Rapporteur assessment received
          ↓
Issue-by-issue review
          ↓
Scientific / regulatory owner assigned
          ↓
Evidence checked
          ↓
Response strategy agreed
          ↓
CHMP interaction

The assessment report should be treated as a controlled regulatory document and not merely as background reading.

25. Oral Explanation and Expert Input

Where appropriate, CHMP may allow the MAH or applicant to provide an oral explanation before the opinion is adopted.

An oral explanation is an opportunity to address unresolved scientific or regulatory issues directly with the committee. It does not replace the written submission or the underlying evidence.

CHMP may also seek advice from individual experts on specific questions arising during the assessment.

The involvement of experts does not transfer the legal responsibility for the opinion away from CHMP. The committee remains responsible for adopting the formal scientific conclusion.

For an MAH, preparation for an oral explanation should therefore focus on the precise unresolved issues rather than attempting to repeat the entire written submission.

26. When Is the CHMP Opinion Issued?

Current EMA guidance states that CHMP will issue an opinion on an Article 30 referral within 60 days of the start date of the procedure, with the possibility of extending the assessment period up to 150 days where necessary to consider the available data, oral explanations or expert input.

The applicable timetable for the individual procedure remains controlling.

The opinion is normally adopted during a CHMP plenary meeting.

For regulatory planning, the expected opinion date should therefore be tracked separately from the eventual European Commission decision date. The CHMP opinion is an important milestone, but where a Commission decision is required it is not the end of the legal implementation process.

27. What Can the CHMP Opinion Conclude?

The possible CHMP conclusions depend on the scientific and regulatory findings.

Current EMA guidance identifies possible outcomes including:

1. amendment of the product information and/or variation of the marketing authorisation, as applicable;
2. imposition of conditions on the marketing authorisation;
3. a conclusion that the application does not satisfy the criteria for authorisation, or that the marketing authorisation should be suspended or revoked, as applicable.

Where product information is amended, the CHMP opinion includes the revised harmonised product-information texts as applicable.

Where conditions are imposed, the opinion can define conditions associated with continued authorisation or conditions for lifting a suspension.

The outcome must therefore be read from the adopted opinion and its annexes rather than inferred from the fact that the procedure was initiated.

28. Structure of the CHMP Opinion

The CHMP opinion is more than a short conclusion.

Current EMA guidance indicates that the opinion includes, as applicable:

• the cover page and CHMP voting outcome;
• the list of nationally authorised medicinal products and applications within scope;
• the relevant MAHs or applicants in each Member State;
• the scientific grounds and explanations for the opinion;
• harmonised SmPC, labelling and/or package leaflet texts;
• conditions or restrictions imposed on the marketing authorisations;
• conditions for lifting a suspension, where applicable;
• divergent CHMP views where the opinion was adopted by majority;
• the CHMP assessment report;
• an agreed Direct Healthcare Professional Communication and communication plan, where applicable.

The annexes are therefore essential to understanding the operative regulatory consequences.

A regulatory professional should not rely solely on the headline conclusion when implementing the outcome.

29. Publication of the CHMP Opinion

EMA publishes information about the CHMP opinion through its established communication channels.

Current guidance states that, following the CHMP plenary meeting, EMA publishes a communication summarising the opinion and the amendments to be applied to the product information. The outcome is also reflected in the CHMP meeting highlights.

The full CHMP opinion is published on the procedure page after the European Commission decision.

This creates an important distinction between:

• the immediate public communication of the scientific outcome;
• the later publication of the full opinion;
• the European Commission decision;
• the subsequent publication of final annexes and regulatory documents.

Regulatory surveillance systems should therefore continue monitoring the procedure after the CHMP opinion has been announced.

30. Re-Examination of the CHMP Opinion

The MAH or applicant has a defined right to request re-examination of the CHMP opinion.

Current EMA guidance states that the MAH or applicant must notify the Agency in writing of the intention to request re-examination within 15 calendar days of receipt of the CHMP opinion.

The detailed grounds for re-examination must then be submitted within 60 calendar days of receipt of the opinion. Failure to meet the applicable deadlines renders the request inadmissible and the opinion becomes final for transmission to the European Commission.

The detailed grounds determine the scope of the re-examination. The request can concern all aspects of the opinion or only specified aspects.

The re-examination process therefore has two distinct procedural acts:

CHMP opinion received
        ↓
Within 15 calendar days
Notice of intention
        ↓
Within 60 calendar days of receipt
Detailed grounds
        ↓
CHMP re-examination
        ↓
Final CHMP opinion

Current EMA guidance describes a re-examination assessment timetable culminating in a CHMP opinion within 60 calendar days of receipt of the detailed grounds, subject to the applicable procedural framework.

For an MAH, the 15-day intention deadline should be treated as a critical regulatory deadline. A company should therefore begin its assessment of the opinion immediately upon receipt rather than waiting for internal strategic decisions to be finalised near the deadline.

31. Re-Examination Is a Defined Regulatory Process

Re-examination is not a general opportunity to reopen the entire Article 30 assessment. It is a defined procedural mechanism for challenging the adopted CHMP opinion within the applicable legal and procedural framework.

The detailed grounds submitted by the MAH or applicant determine the scope of the re-examination. The re-examination addresses the aspects of the CHMP opinion identified in those grounds rather than creating an unrestricted second assessment.

Current EMA guidance states that no new data may be introduced at the re-examination stage. The MAH may nevertheless request consultation of a scientific advisory group or an ad-hoc expert group where appropriate, and such a request should be made as early as possible and no later than submission of the detailed grounds.

New (co-)rapporteurs are appointed for the re-examination. CHMP concludes its assessment and adopts a final opinion within 60 calendar days of receipt of the detailed grounds.

The regulatory significance is substantial: the re-examination should be treated as a tightly controlled response to identified grounds, supported by the existing evidentiary record.

32. The Re-Examination Timetable

The re-examination timetable begins with receipt by EMA of the detailed grounds for the request.

The current EMA guidance describes the following principal milestones:

Day 0       Receipt of detailed grounds
            ↓
Day 30      Circulation of new (co-)rapporteur assessment report(s)
            ↓
Day 40      Written comments from CHMP members
            ↓
Day 60      CHMP discussion and adoption of final opinion

These dates describe the guidance timetable and should not be used instead of the procedure-specific arrangements communicated by EMA.

The MAH should therefore maintain two distinct clocks:

• the legal deadline for notification of the intention to request re-examination and submission of the detailed grounds;
• the subsequent CHMP assessment timetable.

Missing the first deadline can prevent the re-examination from proceeding at all.

33. Withdrawal of a Re-Examination Request

A request for re-examination can itself be withdrawn.

Where the request is withdrawn, the initial CHMP opinion immediately becomes the final opinion and proceeds to the next stage of the Union procedure.

The regulatory team should therefore maintain a clear status for the re-examination process rather than treating the initial CHMP opinion as permanently provisional.

The relevant sequence is:

Initial CHMP opinion
       ↓
No re-examination requested
       ↓
Initial opinion becomes final

OR

Initial CHMP opinion
       ↓
Re-examination requested
       ↓
Final CHMP opinion after re-examination

OR

Initial CHMP opinion
       ↓
Re-examination requested
       ↓
Request withdrawn
       ↓
Initial opinion becomes final

This distinction matters when determining which product-information wording and regulatory conclusions are ready for implementation.

34. Translation of the Final Product Information

Where the CHMP opinion contains revised product information, the final regulatory process requires translation of the relevant annexes.

Current EMA guidance states that the MAH must provide translations of the harmonised SmPC and/or labelling and/or package leaflet, as applicable, into the EU languages. Where the product is authorised in Iceland or Norway, the applicable Icelandic and Norwegian translations are also included.

The translation process is structured around defined procedural milestones.

The current guidance provides that translations are made available to Member State contact points for linguistic checking by Day +5 after adoption of the opinion. Member States may provide linguistic comments until Day +19, and the MAH should submit the amended translations together with the completed QRD Form 2 by Day +22.

Translation is therefore part of the regulatory implementation process, not a post-procedural editorial exercise.

35. Linguistic Review and Regulatory Consistency

The linguistic review should preserve the scientific and regulatory meaning of the adopted CHMP position.

The objective is not to reopen scientific questions or introduce national divergence. The translated product information should accurately represent the agreed harmonised text in each applicable language.

For the MAH, this creates an important quality-control requirement. The organisation should ensure that:

• the approved English source text is controlled;
• translators work from the correct final version;
• regulatory terminology is used consistently;
• changes introduced during linguistic review are tracked;
• national comments are assessed and incorporated appropriately;
• the final translations correspond to the adopted CHMP wording.

The translation process should therefore remain under regulatory governance rather than being treated solely as a language-services activity.

36. The CHMP Opinion Becomes Final

The CHMP opinion becomes final when the applicable re-examination period has passed without an admissible request, or when the re-examination procedure has been completed.

Where no request for re-examination is received within 15 calendar days of receipt of the opinion by the MAH or applicant, the opinion is considered final.

Where re-examination occurs, the final CHMP opinion is the opinion adopted at the conclusion of that process.

This is a critical status transition in the regulatory lifecycle. The company should update its internal regulatory database, product-information control system and implementation tracker to distinguish clearly between:

• draft or proposed wording;
• initial CHMP opinion;
• opinion subject to possible re-examination;
• final CHMP opinion;
• European Commission decision;
• implemented national authorisations.

Confusing these states can lead to premature implementation or use of superseded wording.

37. Transmission to the European Commission

After the CHMP opinion becomes final, EMA, the MAH and the relevant national competent authorities complete the translation process and transmit the applicable material to the European Commission.

The European Commission then begins the decision-making process that leads to a binding decision addressed to the Member States.

The Commission decision is therefore a distinct legal step following the scientific opinion of CHMP.

This distinction is fundamental to understanding Union referral procedures:

CHMP scientific assessment
          ↓
CHMP opinion
          ↓
Re-examination period / re-examination
          ↓
Final CHMP opinion
          ↓
European Commission decision
          ↓
National implementation

The CHMP opinion establishes the scientific conclusion of the committee; the Commission decision provides the Union-level legally binding outcome for the Member States.

38. The European Commission Decision

The European Commission starts its decision-making process after receiving the final CHMP opinion and the finalised translations.

The resulting Commission decision is binding on the Member States concerned by the Article 30 referral.

For the MAH, the Commission decision is therefore the principal Union legal instrument that determines the final regulatory outcome following the referral.

The company should compare the Commission decision with the final CHMP opinion and the product-information annexes before initiating implementation activities.

The regulatory implementation package should identify, as applicable:

• the medicinal products and national authorisations within scope;
• the regulatory outcome;
• required variations or amendments;
• harmonised product information;
• conditions or restrictions;
• implementation deadlines;
• any communication measures;
• any remaining regulatory obligations.

The Commission decision should be retained as a controlled regulatory record.

39. National Implementation of the Commission Decision

An Article 30 referral concerns nationally authorised medicinal products. The Union decision therefore has to be reflected in the relevant national marketing authorisations.

The implementation phase is not simply a matter of copying the Commission decision into national systems. The national competent authorities must implement the binding Union outcome in accordance with the applicable regulatory framework and the implementation arrangements for the referral.

The MAH should maintain a country-by-country implementation tracker covering at least:

This tracker should reconcile against the Union-level Commission decision.

40. The Role of the CMDh in Implementation

For nationally authorised medicinal products, implementation may involve the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh).

EMA's current Article 30 guidance refers to CMDh recommendations for implementation of Commission Decisions and CMDh post-referral procedural guidance.

The CMDh role is important because the referral outcome must be translated into coordinated national regulatory action across Member States.

The MAH should therefore monitor both the EMA referral procedure and the applicable CMDh implementation guidance.

A referral should not be considered operationally complete merely because the Commission decision has been adopted. The national implementation phase must also be controlled and documented.

41. Product Information After an Article 30 Referral

The central practical outcome of many Article 30 referrals is harmonisation of product information.

Where the CHMP opinion requires amendments, the harmonised wording may cover one or more of:

• Summary of Product Characteristics;
• labelling;
• package leaflet.

The final wording should be treated as the regulatory source of truth for the affected national authorisations, subject to the precise scope of the Commission decision and national implementation.

The MAH should ensure that obsolete national wording is removed from controlled regulatory systems and replaced with the authorised harmonised version.

This requires coordination among regulatory affairs, pharmacovigilance, medical, quality, artwork, labelling and supply functions where the change affects operational materials.

42. Implementation of Safety-Related Product Information Changes

An Article 30 referral is primarily a harmonisation procedure, but its outcome can have direct safety implications.

Where the harmonised product information introduces or changes safety information, the MAH should assess the operational consequences across the pharmacovigilance system.

Potential activities can include:

• updating the Company Core Safety Information where appropriate;
• updating safety reference information;
• revising signal-detection search strategies;
• updating case-processing conventions where necessary;
• reviewing aggregate-report content;
• updating risk-management documentation where applicable;
• implementing required healthcare-professional communications;
• ensuring that safety information is reflected consistently across controlled systems.

The regulatory implementation of the referral and the pharmacovigilance implementation should therefore be connected through a controlled change-management process.

43. Direct Healthcare Professional Communication

Where applicable, the CHMP opinion may include a Direct Healthcare Professional Communication (DHPC) and communication plan agreed by CHMP.

A DHPC should not be treated as an optional communication initiative when it forms part of the agreed regulatory outcome.

The MAH should establish a controlled implementation process covering:

1. the final approved communication content;
2. the affected healthcare professionals or other recipients;
3. Member State implementation requirements;
4. translation and linguistic review;
5. distribution arrangements;
6. documentation of completion;
7. reconciliation of the communication with the final product information.

The communication plan should remain aligned with the regulatory wording adopted through the referral.

44. Regulatory Records and Audit Trail

The complete Article 30 procedure should leave an auditable regulatory record.

At minimum, the company should be able to reconstruct:

National divergence
      ↓
Referral notification
      ↓
Procedure initiation
      ↓
Scope confirmation
      ↓
MAH submission
      ↓
CHMP questions
      ↓
MAH responses
      ↓
Rapporteur assessment
      ↓
Outstanding issues / oral explanation, if applicable
      ↓
CHMP opinion
      ↓
Re-examination, if applicable
      ↓
Final CHMP opinion
      ↓
Translations
      ↓
Commission decision
      ↓
National implementation
      ↓
Post-referral monitoring

The record should preserve the versions of submissions, responses, product information, assessment reports, opinions, decisions and implementation evidence that were relied upon at each stage.

This is particularly important where a referral modifies long-standing national differences and later regulatory activities need to determine which wording was authoritative at a particular point in time.

45. Publication After the Commission Decision

Publication continues after the European Commission has adopted its decision.

Current EMA guidance states that the CHMP assessment report is published on the procedure page, in English, approximately one week after adoption of the Commission decision.

Within four weeks of the Commission decision, the CHMP opinion and its annexes in all EU languages are published on the procedure page. The procedure page is also updated to show the date of the Commission decision.

This publication sequence is important when performing regulatory intelligence or reconstructing the history of a product-information change.

The existence of a public procedure page also means that a company should not rely solely on internal regulatory records when monitoring the status of a referral. EMA publications can provide an independent confirmation of the final procedural outcome.

46. When the Article 30 Procedure Is Operationally Complete

An Article 30 referral should be considered operationally complete only when the regulatory consequences of the Commission decision have been implemented and documented for the affected national authorisations.

The following should normally be reconciled before closure:

• final CHMP opinion;
• applicable re-examination outcome;
• final translations;
• Commission decision;
• national implementation requirements;
• approved national product information;
• communication requirements;
• outstanding conditions or restrictions;
• regulatory commitments;
• internal safety-system updates where applicable.

The exact closure criteria should be adapted to the outcome of the individual referral.

A procedure-closure checklist should therefore be outcome-based rather than simply triggered by receipt of the Commission decision.

47. Post-Referral Regulatory Surveillance

Harmonisation does not end the need for pharmacovigilance or regulatory surveillance.

Following implementation, the MAH should monitor whether the harmonised regulatory position remains consistent with subsequent evidence and regulatory developments.

Relevant sources can include:

• individual case safety reports;
• signal detection;
• aggregate reports;
• literature surveillance;
• post-authorisation studies;
• regulatory authority communications;
• subsequent variations;
• safety referrals;
• changes to clinical practice.

The Article 30 outcome should become part of the product's continuing regulatory history rather than being treated as an isolated historical event.

Where subsequent evidence creates a new safety or efficacy concern, a different Union procedure may become relevant depending on the nature of the issue. An Article 30 referral should not be used retrospectively to characterise every later regulatory action involving the same product.

48. Article 30 Versus Article 31: A Practical Distinction

Article 30 and Article 31 referrals can both involve CHMP assessment and nationally authorised medicinal products, but their regulatory purposes differ.

Article 30 is fundamentally a harmonisation mechanism addressing divergent national decisions or promoting harmonisation of nationally authorised medicines.

Article 31 is a broader Union referral mechanism used where the Union interest is involved because of concerns relating to the quality, safety or efficacy of a medicinal product or class of medicines.

The distinction matters for pharmacovigilance governance. A company should not classify a referral solely by the fact that CHMP is involved. The legal basis and reason for referral determine the applicable procedural framework.

A useful first question when a new Union referral appears is therefore:

What regulatory problem is the referral legally intended to resolve?

Only after that question is answered should the company map the procedure to its internal regulatory and pharmacovigilance processes.

49. Article 30 Versus Article 13: A Practical Distinction

Article 13 referrals arise in the context of mutual-recognition or decentralised procedures when Member States cannot agree on certain variations and the disagreement concerns a potential serious risk to public health.

Article 30 referrals instead address divergent national decisions concerning the authorisation, suspension or revocation of a medicinal product and are used to promote harmonisation.

The two procedures can therefore look superficially similar because both involve multiple Member States and may result in a CHMP assessment, but their legal triggers and procedural contexts are different.

For regulatory operations, the legal basis should be recorded at the beginning of the procedure. This prevents later confusion when determining which timetable, submission requirements and implementation mechanism apply.

50. Article 30 and the QPPV's Regulatory Interface

Although Article 30 is a regulatory harmonisation procedure rather than a pharmacovigilance procedure, its outcome can materially affect the pharmacovigilance system.

The QPPV should be aware of Article 30 referrals affecting medicinal products for which they have pharmacovigilance responsibility, particularly when the divergence concerns:

• indications;
• contraindications;
• warnings and precautions;
• adverse reactions;
• posology with safety implications;
• special populations;
• risk-minimisation information;
• other clinically relevant product-information elements.

The QPPV should not assume that receipt of a final Commission decision automatically updates the pharmacovigilance system. The regulatory change must be translated into controlled operational actions.

Depending on the outcome, this may require coordination with regulatory affairs, medical safety, signal management, aggregate reporting, risk management, labelling and safety-communication functions.

The QPPV's role is therefore primarily one of pharmacovigilance governance at the regulatory interface: ensuring that material safety consequences of the harmonisation outcome are identified, assessed and incorporated into the pharmacovigilance system where required.

51. Inspection Considerations for Article 30 Referrals

An inspection may examine whether the organisation correctly recognised and implemented an Article 30 outcome affecting a medicinal product under its pharmacovigilance responsibility.

Potential inspection questions include:

• How did the company identify the referral?
• Who assessed its relevance to pharmacovigilance?
• How was the final outcome communicated internally?
• Were safety-related product-information changes incorporated into the appropriate systems?
• Were required communications implemented?
• Were relevant signal-detection strategies reviewed?
• Were risk-management documents updated where required?
• How were implementation dates controlled?
• Can the company demonstrate that obsolete product information was replaced?
• Is there an auditable record connecting the Commission decision to operational implementation?

The expected answer should not depend on individual recollection. The organisation should be able to demonstrate a controlled process and documentary evidence.

52. Common Implementation Failures

Several implementation failures are particularly avoidable.

Treating the CHMP opinion as the final legal instrument

The CHMP opinion is a critical scientific milestone, but the Article 30 process proceeds to a European Commission decision. Internal implementation should be based on the applicable final legal outcome.

Missing the re-examination window

The initial 15-calendar-day notification period is a legal procedural deadline. Failure to act within it can remove the possibility of requesting re-examination.

Treating translation as administrative housekeeping

Translation is part of the controlled implementation of the final product information. Poor version control can introduce unintended divergence.

Closing the procedure after the Commission decision

The national implementation and internal system changes may still be outstanding.

Updating product information without updating connected systems

A safety-related wording change may require corresponding updates in pharmacovigilance, medical, regulatory and risk-management processes.

Losing the historical record

The previous national divergences remain relevant to understanding why the referral occurred and how the final harmonised position was reached.

53. Practical Article 30 Workflow for an MAH

A robust internal workflow can be represented as follows:

1. Detect referral
       ↓
2. Identify legal basis and scope
       ↓
3. Establish procedural ownership
       ↓
4. Confirm IRIS contact and governance
       ↓
5. Map national divergences
       ↓
6. Inventory ongoing regulatory procedures
       ↓
7. Build scientific and regulatory evidence package
       ↓
8. Prepare harmonised product information
       ↓
9. Submit through the applicable EMA electronic system
       ↓
10. Track LoQ / LoOI and assessment reports
       ↓
11. Prepare written and oral responses as applicable
       ↓
12. Review CHMP opinion
       ↓
13. Assess re-examination option
       ↓
14. Finalise translations
       ↓
15. Track Commission decision
       ↓
16. Implement nationally
       ↓
17. Update safety and regulatory systems
       ↓
18. Close and archive the procedure
       ↓
19. Continue post-referral surveillance

The value of such a workflow is not the diagram itself. Its value is that every transition has an accountable owner, a controlled document and a defined completion criterion.

54. Key Takeaways

An Article 30 referral is a Union mechanism for resolving divergent national regulatory positions and promoting harmonisation of nationally authorised medicines.

The procedure moves through several distinct regulatory states: initiation, assessment, CHMP opinion, possible re-examination, final opinion, Commission decision and national implementation.

The distinction between the CHMP opinion and the European Commission decision is fundamental. The former represents the committee's scientific conclusion; the latter establishes the binding Union outcome addressed to the Member States.

The MAH's responsibility extends beyond submitting scientific responses. It includes maintaining controlled procedural communications, providing a defensible harmonised product-information proposal, managing translations, monitoring procedural deadlines and implementing the final outcome across the affected national authorisations.

For the QPPV, the most important interface occurs when the referral changes safety-relevant product information or otherwise affects the benefit-risk profile. The QPPV should ensure that such changes are translated into appropriate pharmacovigilance actions and that the implementation is documented.

Finally, the referral should remain part of the product's continuing regulatory history. Publication of the assessment report, CHMP opinion and Commission decision provides an external record that can support regulatory intelligence, future inspections and reconstruction of the product's regulatory history.

References

1. European Medicines Agency. Questions and answers on Article 30 referral procedures. EMA/457319/2016. Revised July 2026.
2. European Parliament and Council. Directive 2001/83/EC on the Community code relating to medicinal products for human use, as amended.
3. European Medicines Agency. Referral procedures: human medicines.
4. European Medicines Agency. What EMA publishes and when — Guide to information on human medicines evaluated by EMA.
5. European Commission. Notice to Applicants, Volume 2A, Procedures for marketing authorisation, Chapter 6: Decision Making.
6. CMDh. Recommendations for implementation of Commission Decisions or CMDh agreements following Union referral procedures where the marketing authorisation is maintained or varied.
7. CMDh. Questions and answers — post-referrals phase.

55. Common Regulatory Failure: Confusing Harmonisation With Automatic Uniformity

Harmonisation does not mean that every administrative element of every national authorisation becomes identical in every respect.

The Union procedure establishes the regulatory position within the scope of the referral. National authorities then implement that outcome within their respective legal and administrative frameworks.

The MAH should therefore distinguish between:

• harmonised scientific and regulatory conclusions;
• harmonised product-information wording;
• national administrative implementation;
• national procedural records.

The objective is regulatory consistency within the scope of the referral, not the elimination of every national administrative difference.

56. Managing Article 30 Changes Through Change Control

Article 30 implementation should be managed as a controlled regulatory change when it affects the company's systems, documents or processes.

The change-control record should identify:

1. the source of the change;
2. the affected products and markets;
3. the regulatory effective date;
4. the required actions;
5. responsible functions;
6. required approvals;
7. implementation evidence;
8. verification of completion.

Where safety information changes, the change-control assessment should explicitly consider pharmacovigilance consequences.

Where product information changes without a direct safety consequence, the organisation should still document the regulatory impact and implementation rationale.

This creates a defensible audit trail between the external regulatory decision and the internal operational change.

57. Relationship With Lifecycle Variations

An Article 30 outcome can require subsequent regulatory actions within the normal lifecycle management framework.

The referral itself should not be confused with the variation procedure used to implement or maintain changes after the Union decision.

The regulatory team should distinguish:

Article 30
Union-level assessment and harmonisation

versus

Lifecycle variation
National regulatory implementation or subsequent maintenance

The precise implementation mechanism depends on the legal framework applicable to the affected authorisations and the instructions associated with the Commission Decision.

The existence of an Article 30 outcome should therefore be recorded as regulatory history even after the corresponding implementation variations have been completed.

58. Relationship With Future Variations

Once harmonised product information has been implemented, future changes should be assessed against the harmonised regulatory baseline.

The Article 30 outcome becomes part of the product's regulatory history and may influence the interpretation of subsequent variation proposals.

Regulatory teams should avoid reverting inadvertently to a pre-referral national position through later lifecycle activity.

A practical control is to maintain the final harmonised product information as the baseline against which subsequent regulatory changes are assessed.

Where a later variation affects the same section of product information, the regulatory rationale should recognise the previous Article 30 outcome where relevant.

59. Regulatory Intelligence and Article 30 Referrals

Article 30 referrals are important sources of regulatory intelligence because they reveal how divergent national positions were evaluated at Union level.

The procedure page, CHMP assessment report, opinion and Commission Decision can provide information about:

• the scientific question;
• the evidence considered;
• the reasons for the divergent national positions;
• the reasoning behind the harmonised conclusion;
• the final product-information changes.

Regulatory intelligence teams should therefore retain links to the authoritative EMA procedure page and relevant Union legal documents rather than relying exclusively on secondary summaries.

For historical reconstruction, the publication date should be distinguished from the date on which the underlying regulatory decision was adopted.

60. Reading the Primary Documents in the Correct Order

For a live or historical Article 30 assessment, the following document hierarchy is useful:

1. Directive 2001/83/EC — establishes the legal framework.
2. Formal referral notification — establishes the scope of the procedure.
3. EMA Article 30 procedural guidance — explains operational handling.
4. CHMP assessment report — explains the scientific assessment.
5. CHMP opinion and annexes — establish the committee's conclusion and proposed regulatory outcome.
6. European Commission Decision — establishes the Union-level legally binding decision.
7. CMDh implementation information — supports implementation for nationally authorised products where applicable.
8. National regulatory records — establish the final national implementation.

Secondary articles and regulatory summaries can be useful for orientation, but they should not replace the primary documents when determining the legal or procedural position.

61. A Practical Article 30 Workflow for Regulatory Affairs

A regulatory organisation can operationalise the procedure using the following workflow:

1. Detect or receive information about divergent national decisions
                         ↓
2. Confirm the legal basis and scope
                         ↓
3. Map affected products and national authorisations
                         ↓
4. Identify the procedural contact and governance team
                         ↓
5. Establish the referral timetable
                         ↓
6. Collect the underlying national regulatory history
                         ↓
7. Prepare the MAH/applicant submission
                         ↓
8. Respond to CHMP questions
                         ↓
9. Manage assessment and outstanding issues
                         ↓
10. Prepare for CHMP opinion
                         ↓
11. Manage re-examination if required
                         ↓
12. Control final product-information translations
                         ↓
13. Track the Commission Decision
                         ↓
14. Implement across affected national authorisations
                         ↓
15. Verify product-information and system changes
                         ↓
16. Close the procedure with an auditable record
                         ↓
17. Monitor subsequent regulatory consequences

The workflow should be adapted to the actual procedure timetable and outcome. It should not substitute for the timetable communicated by EMA.

62. Practical Article 30 Checklist

Before closure, the regulatory lead should be able to answer the following questions.

Legal basis and scope

• [ ] Is the Article 30 legal basis documented?
• [ ] Is the reason for the referral clearly defined?
• [ ] Are all affected medicinal products identified?
• [ ] Are all affected national marketing authorisations identified?

Procedure

• [ ] Is the EMA procedure contact identified?
• [ ] Is the timetable controlled?
• [ ] Were all submissions made within the applicable deadlines?
• [ ] Were CHMP questions and outstanding issues tracked?
• [ ] Was any oral explanation appropriately documented?

Opinion and decision

• [ ] Is the CHMP opinion controlled?
• [ ] Was the re-examination period assessed?
• [ ] If re-examination occurred, is the final opinion controlled?
• [ ] Is the Commission Decision available?

Implementation

• [ ] Are final translations controlled?
• [ ] Is the harmonised product information approved and implemented?
• [ ] Are national implementation actions complete?
• [ ] Are implementation dates documented?
• [ ] Are communication requirements complete?

Pharmacovigilance interface

• [ ] Was a pharmacovigilance impact assessment performed where appropriate?
• [ ] Were safety-reference documents updated where required?
• [ ] Were relevant safety-system changes implemented?
• [ ] Were aggregate-reporting or signal-management consequences assessed?

Closure

• [ ] Is the complete regulatory audit trail retained?
• [ ] Is the final regulatory baseline clear?
• [ ] Are outstanding commitments documented?
• [ ] Is post-referral monitoring assigned where necessary?

63. What the QPPV Should Know About Article 30

The QPPV does not own the Article 30 regulatory procedure simply because the outcome may affect safety information.

The QPPV's responsibility is to ensure that relevant pharmacovigilance consequences are recognised and appropriately incorporated into the pharmacovigilance system.

The QPPV should therefore know:

• why the referral was initiated;
• which products and markets are affected;
• whether safety information changed;
• whether the change affects a known or potential risk;
• whether risk-management measures are affected;
• whether safety-reference information requires updating;
• whether signal detection or case-processing procedures require modification;
• whether the outcome affects ongoing aggregate-reporting assessments.

The QPPV should also ensure that regulatory and pharmacovigilance teams have a controlled mechanism for communicating material changes.

This is a governance responsibility rather than a requirement for the QPPV to manage every regulatory submission personally.

64. Article 30 and the Benefit-Risk Assessment

A harmonised regulatory decision can alter the information available to prescribers and patients and may therefore affect the product's benefit-risk framework.

The significance depends on the substance of the referral outcome.

A change to an administrative element of product information may have little direct pharmacovigilance consequence. A change introducing a contraindication, strengthening a warning, restricting an indication or identifying a new adverse reaction may have substantial consequences.

The organisation should therefore assess the content and significance of the outcome, not merely the existence of a regulatory change.

Where the outcome changes the characterisation of a safety concern, the appropriate pharmacovigilance governance processes should be triggered.

65. Article 30 Is a Regulatory History, Not Just a Procedure Number

A referral number alone does not describe the regulatory significance of an Article 30 procedure.

The durable regulatory record should connect:

Why the divergence existed
        ↓
What evidence was reviewed
        ↓
What CHMP concluded
        ↓
What the Commission decided
        ↓
What each Member State implemented
        ↓
What the final product information became
        ↓
What subsequent regulatory consequences followed

This historical chain is particularly valuable when products have long lifecycles and successive regulatory teams.

A future regulatory professional should be able to understand the reason for a harmonised position without reconstructing the entire historical record from disconnected documents.

66. Key Takeaways

Article 30 of Directive 2001/83/EC provides a Union mechanism for addressing qualifying divergent national decisions concerning the same medicinal product and establishing a harmonised regulatory position.

The most important principles are:

1. The legal trigger matters. Not every difference between national product information constitutes an Article 30 situation.
2. The national regulatory history matters. The underlying decisions should be examined rather than relying only on textual differences.
3. CHMP provides the scientific assessment. The committee evaluates the issue and adopts an opinion.
4. Re-examination is a defined procedural right. It is not an unrestricted second assessment.
5. The Commission Decision is a distinct legal step. The CHMP opinion and the Commission Decision should not be treated as interchangeable.
6. National implementation must be controlled. A Union decision still has to be reflected in the affected national authorisations.
7. Product information is a central implementation output. The final harmonised wording becomes the regulatory baseline within the scope of the decision.
8. The QPPV interface is important when safety information changes. Regulatory outcomes with pharmacovigilance consequences must be translated into appropriate safety-system actions.
9. The audit trail matters. A defensible system can reconstruct the procedure from referral through implementation.
10. Primary sources should control interpretation. Directive 2001/83/EC, EMA procedural guidance, CHMP documents, the Commission Decision and national implementation records form the core evidence base.

References

1. European Parliament and Council. Directive 2001/83/EC on the Community code relating to medicinal products for human use. In particular Articles 30 and 32–34.

2. European Medicines Agency. Questions and answers on Article 30 referral procedures. EMA/457319/2016 Rev. 1. Current EMA version updated July 2026.

3. European Medicines Agency. Questions and answers on Article 30 referral procedures — PDF version. EMA/457319/2016 Rev. 1.

4. European Medicines Agency. What EMA publishes and when — Guide to information on human medicines evaluated by EMA.

5. European Medicines Agency. CMDh procedural guidance for referral procedures and implementation of Commission Decisions, where applicable to nationally authorised medicines.

6. European Medicines Agency. Post-authorisation procedural advice for users of the centralised procedure, where relevant to implementation principles and regulatory lifecycle management.

7. European Commission. Notice to applicants — The rules governing medicinal products in the European Union.

Regulatory Note

This article is intended as a practical regulatory-affairs explanation of the Article 30 referral mechanism. It is not a substitute for the applicable legislation, formal referral documentation, current EMA procedural guidance, a CHMP opinion or a European Commission Decision.

For a live procedure, the current version of Directive 2001/83/EC and the current EMA procedural guidance should be checked before relying on any timetable, submission requirement or implementation instruction.

Procedural guidance can change. The authoritative position for a particular referral is the legal framework and the procedure-specific information issued by the competent Union and national authorities.